Hyderabad, July 26 -- In a significant development, a Hyderabad-based startup has raised hopes of relief for acute liver disease patients.

Tulsi Therapeutics has developed Tulsi-28X, a therapeutic product that has reversed liver fibrosis in animal trials.

The startup incubated at the ASPIRE-BioNEST at the University of Hyderabad (UoH) claimed that it is the world's first successful animal trial of a novel stem cell-exosome combination therapy for chronic liver failure.

The regenerative therapy is derived from Wharton's Jelly mesenchymal stem cells and their native exosomes-a combination never before tested in any animal model worldwide.

Biotech industry

The Hyderabad Company fully developed the platform during three years of research...